591394 Disclosed are dacarbazine analogues as represented by the general formulae (I) and (II), wherein R is selected from H, CH3, and CH2OH

USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER In one aspect, the present invention relates to a composition comprising at least one of y-tocotrienol or 6-tocotrienol and (2R,3S)-N-carboxy-3-phenylisoserine, N-tert-butylester, 13-ester with 5,20-epoxy-1,2,4,7,10,13-hexahydroxytax-11-en-9 one-4-acetate-2-benzoate, trihydrate (Docetaxel) and/or (5Z)-5 (dimethylaminohydrazinylidene)imidazole-4-carboxamide (Dacarbazine). In a further aspect, the present invention relates to a method of ...

FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely oncology and radiology, and may be used for treating stage IIA Hodgkin's lymphoma. That is ensured by 3-4 therapeutic courses of chemotherapy by the scheme ABVD - adriablastine, bleomycine, vinblastine, dacarbazine. It is followed by chemotherapy by the scheme AVB - adriablastine, vinblastine, dacarbazine. From the 2nd day of the AVD course, the radiation therapy covering initially involved zones is applied at single basic dose 1...

Disclosed is the use of an antibody-drug conjugate compound comprising an anti-CD30 antibody conjugated to an auristatin compound in the manufacture of a medicament for use in combination therapy with a chemotherapeutic regimen comprising doxorubicin, bleomycin, vinblastine, and dacarbazine for the treatment of Hodgkin lymphoma in a subject. Further disclosed is the use of an antibody-drug conjugate compound comprising an anti-CD30 antibody conjugated to an auristatin compound in the manufacture...

PURPOSE: A pharmaceutical composition containing 3-caffeoyl-4-dihydrocaffeoyl quinic acid(CDCQ) is provided to suppress cell basal lamina digesting enzyme MMP-2 and MMP-9 activities and prevent cancer cell metastasis. CONSTITUTION: A pharmaceutical composition for suppressing cancer metastasis contains 3-caffeoyl-4-dihydrocaffeoylquinic acid. The composition suppresses activity of MMP-2(matrix metalloprotease-2) or MMP-9(matrix metalloprotease-9). A health food for preventing metastasis contains...

In the present invention there is disclosed a pharmaceutical composition containing cyclopeptide cyclo-(Arg-Gly-Asp-D-Phe-NMe-Val) and/or a physiologically acceptable salt thereof and at least one chemotherapeutic agent and/or physiologically acceptable salts thereof being selected from the group consisting of a) alkylating agents selected from a group consisting of busulfan carboplatin carmustine cisplatin cyclophosphamide dacarbazine ifosfamide and lomustine b) antibiotics selected from a grou...

The present invention is directed to a method of preventing cancer or preventing the recurrence of cancer after undergoing a cancer treatment by administering a composition comprising at least one of [gamma]-tocotrienol or [delta]-tocotrienol, wherein the cancer is selected from the group consisting of melanoma, prostate cancer, prostate intraepithelial neoplasia, colon cancer, liver cancer, bladder cancer, breast cancer and lung cancer. The present invention is further directed to a composition...

A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution.

A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion dacarbazine has a greater anti-cancer efficacy than when applied as a free solution.

The present invention is directed to a method of preventing cancer or preventing the recurrence of cancer after undergoing a cancer treatment by administering a composition comprising at least one of ?-tocotrienol or ?- tocotrienol, wherein the cancer is selected from the group consisting of melanoma, prostate cancer, prostate intraepithelial neoplasia, colon cancer, liver cancer, bladder cancer, breast cancer and lung cancer. The present invention is further directed to a composition comprising...